KENDALL ESTES: Open Payments
NPI 1083476436 · REFORM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,083 in 57 payments from 16 companies in 2025. Trend: 2023 $0 · 2024 $1,096 · 2025 $1,083
Food & beverage: $1,083
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $194 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $132 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $108 |
| Otsuka America Pharmaceutical, Inc. | 5 | $88 |
| Ardelyx, Inc. | 4 | $87 |
| Novo Nordisk Inc | 4 | $74 |
| Neurocrine BioSciences, Inc. | 4 | $74 |
| Vanda Pharmaceuticals Inc. | 2 | $65 |
| Lilly USA, LLC | 3 | $55 |
| Axsome Therapeutics, Inc. | 3 | $52 |
Products named: CAPLYTA, Kerendia, REXULTI, IBSRELA, VRAYLAR, INGREZZA, FANAPT, MOUNJARO.
Industry payments across AL — which companies pay providers there.
